Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial-Reference-Cited by-同舟云学术

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Published:2016-07-14 Issue:37 Volume:7 Page:60647-60656
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Zhang Pin¹,Yin Yi²,Mo Hongnan¹,Zhang Bailin³,Wang Xiang³,Li Qing¹,Yuan Peng¹,Wang Jiayu¹,Zheng Shan⁴,Cai Ruigang¹,Ma Fei¹,Fan Yin¹,Xu Binghe¹

Affiliation:

1. Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2. Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China

3. Department of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

4. Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platinum chemotherapy for early triple-negative breast cancer;The Breast;2024-06

2. A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC);Journal of Nanoparticle Research;2024-05

3. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis;BMC Cancer;2024-04-09

4. Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis;Systematic Reviews;2024-04-04

5. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies;eBioMedicine;2024-04